Development Pipeline
LSO is focusing on three cancers for the initial development of Litx™: Hepatoma, Metastatic Colorectal Cancer and Glioma.
Current Clinical Trials
Phase III trials are underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver.
Light Sciences (now LSO) was founded in 1994 to find and produce a commercially viable light-activated drug product to treat patients with solid tumor cancers. LSO has built a strong development organization with an efficient team overseeing engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has developed a low-cost, palm-sized, single-use, disposable light-activation unit that is designed for easy use by physicians and to provide tolerable, effective, and repeatable treatments to cancer patients.
LSO completed a $67 million Series A preferred financing in late 2005. A $30 million Series B preferred financing was completed in June 2007.